Glucocorticoid-Induced Ocular Hypertension and Glaucoma

Devon Hori Harvey; Chenna Kesavulu Sugali; Weiming Mao

doi:10.2147/OPTH.S442749

Glucocorticoid-Induced Ocular Hypertension and Glaucoma

Clin Ophthalmol. 2024 Feb 16:18:481-505. doi: 10.2147/OPTH.S442749. eCollection 2024.

Authors

Devon Hori Harvey^{1

2}, Chenna Kesavulu Sugali^{1

2}, Weiming Mao^{1

2

3

4

5}

Affiliations

¹ Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA.
² Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
³ Department of Biochemistry & Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
⁴ Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA.
⁵ Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.

Abstract

Glucocorticoid (GC) therapy is indicated in many diseases, including ocular diseases. An important side-effect of GC therapy is GC-induced ocular hypertension (GIOHT), which may cause irreversible blindness known as GC-induced glaucoma (GIG). Here, we reviewed the pathological changes that contribute to GIOHT including in the trabecular meshwork and Schlemm's canal at cellular and molecular levels. We also discussed the clinical aspects of GIOHT/GIG including disease prevalence, risk factors, the type of GCs, the route of GC administration, and management strategies.

Keywords: aqueous humor outflow; glucocorticoid; intraocular pressure; mechanism; trabecular meshwork; treatment.

Publication types

Review

Abstract

Publication types

Grants and funding